News

New Study Shows How Providers Can Use Apretude To Prevent And Treat HIV In Black Women
A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) ...
The Washington Informer2h
Whitman-Walker Celebrates PrEP Awareness Day; Health Provider Offers Resources, Education, Call to Action
Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...
Managed Healthcare Executive1d
WHO Adds Lenacapavir to Its HIV PrEP Recommendations Amid Underutilization of PrEP and Severe PEPFAR Funding Cutbacks | IAS 2025
As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...
BioSpace14h
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...
Fierce Biotech1d
Merck wades deeper into HIV PrEP waters dominated by Gilead with 2 new late-stage trials
Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...
Managed Healthcare Executive1d
Black Woman Can Successfully Be Started on Long-Acting Apretude for HIV PrEP | IAS 2025
Increasing the use of Apretude among Black women requires not only expanding awareness of the long-acting PrEP regimen in ...
Clinical Trials Arena on MSN17h
MSD progresses once-monthly HIV PrEP into Phase III
Announced at the International AIDS Society (IAS) 2025 conference taking place from 13-17 July in Kigali, Rwanda, MSD has launched two Phase III trials, EXPrESSIVE-10 and EXPrESSIVE-11, which will ...
KVAL on MSN5d
HIV vaccine a closer reality with new HIV PrEP injection
Six months of prevention -- that's how long Lenacapavir, the new drug for HIV prevention lasts.The Food and Drug Administration approved it last month, and desp ...